Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide

M. J. Jenner, Ivana Micallef, A. Z. Rohatiner, S. M. Kelsey, A. C. Newland, J. D. Cavenagh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive disease as an early post-transplant complication. Tissue plasminogen activator was initially felt to be contraindicated since the patient had concomitant pericarditis. Defibrotide was therefore commenced as treatment for veno-occlusive disease. The pericarditis improved but the veno-occlusive disease continued to worsen (peak bilirubin 353 μmol/l). Tissue plasminogen activator followed by a heparin infusion was therefore administered. However, he proceeded to develop haemorrhagic cardiac tamponade that required drainage. Thrombolysis was therefore discontinued and treatment with defibrotide resumed after an interval of 48 h. The veno-occlusive disease gradually resolved and defibrotide was discontinued once the bilirubin had plateaued. He was discharged home on day +52 post-transplant.

Original languageEnglish (US)
Pages (from-to)333-336
Number of pages4
JournalMedical Oncology
Volume17
Issue number4
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Tissue Plasminogen Activator
Pericarditis
Transplants
Bilirubin
Hepatic Veno-Occlusive Disease
Unrelated Donors
Cardiac Tamponade
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Heparin
Drainage
Therapeutics
defibrotide

Keywords

  • Bone marrow transplantation
  • Defibrotide
  • Tissue plasminogen activator
  • Veno-occlusive disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide. / Jenner, M. J.; Micallef, Ivana; Rohatiner, A. Z.; Kelsey, S. M.; Newland, A. C.; Cavenagh, J. D.

In: Medical Oncology, Vol. 17, No. 4, 01.01.2000, p. 333-336.

Research output: Contribution to journalArticle

Jenner, M. J. ; Micallef, Ivana ; Rohatiner, A. Z. ; Kelsey, S. M. ; Newland, A. C. ; Cavenagh, J. D. / Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide. In: Medical Oncology. 2000 ; Vol. 17, No. 4. pp. 333-336.
@article{dea642f1f6664094aaac3f97e7001c74,
title = "Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide",
abstract = "A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive disease as an early post-transplant complication. Tissue plasminogen activator was initially felt to be contraindicated since the patient had concomitant pericarditis. Defibrotide was therefore commenced as treatment for veno-occlusive disease. The pericarditis improved but the veno-occlusive disease continued to worsen (peak bilirubin 353 μmol/l). Tissue plasminogen activator followed by a heparin infusion was therefore administered. However, he proceeded to develop haemorrhagic cardiac tamponade that required drainage. Thrombolysis was therefore discontinued and treatment with defibrotide resumed after an interval of 48 h. The veno-occlusive disease gradually resolved and defibrotide was discontinued once the bilirubin had plateaued. He was discharged home on day +52 post-transplant.",
keywords = "Bone marrow transplantation, Defibrotide, Tissue plasminogen activator, Veno-occlusive disease",
author = "Jenner, {M. J.} and Ivana Micallef and Rohatiner, {A. Z.} and Kelsey, {S. M.} and Newland, {A. C.} and Cavenagh, {J. D.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1007/BF02782200",
language = "English (US)",
volume = "17",
pages = "333--336",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide

AU - Jenner, M. J.

AU - Micallef, Ivana

AU - Rohatiner, A. Z.

AU - Kelsey, S. M.

AU - Newland, A. C.

AU - Cavenagh, J. D.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive disease as an early post-transplant complication. Tissue plasminogen activator was initially felt to be contraindicated since the patient had concomitant pericarditis. Defibrotide was therefore commenced as treatment for veno-occlusive disease. The pericarditis improved but the veno-occlusive disease continued to worsen (peak bilirubin 353 μmol/l). Tissue plasminogen activator followed by a heparin infusion was therefore administered. However, he proceeded to develop haemorrhagic cardiac tamponade that required drainage. Thrombolysis was therefore discontinued and treatment with defibrotide resumed after an interval of 48 h. The veno-occlusive disease gradually resolved and defibrotide was discontinued once the bilirubin had plateaued. He was discharged home on day +52 post-transplant.

AB - A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive disease as an early post-transplant complication. Tissue plasminogen activator was initially felt to be contraindicated since the patient had concomitant pericarditis. Defibrotide was therefore commenced as treatment for veno-occlusive disease. The pericarditis improved but the veno-occlusive disease continued to worsen (peak bilirubin 353 μmol/l). Tissue plasminogen activator followed by a heparin infusion was therefore administered. However, he proceeded to develop haemorrhagic cardiac tamponade that required drainage. Thrombolysis was therefore discontinued and treatment with defibrotide resumed after an interval of 48 h. The veno-occlusive disease gradually resolved and defibrotide was discontinued once the bilirubin had plateaued. He was discharged home on day +52 post-transplant.

KW - Bone marrow transplantation

KW - Defibrotide

KW - Tissue plasminogen activator

KW - Veno-occlusive disease

UR - http://www.scopus.com/inward/record.url?scp=0033758625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033758625&partnerID=8YFLogxK

U2 - 10.1007/BF02782200

DO - 10.1007/BF02782200

M3 - Article

C2 - 11114714

AN - SCOPUS:0033758625

VL - 17

SP - 333

EP - 336

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 4

ER -